Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sage Therapeutic Com (NQ: SAGE )

49.60 -0.63 (-1.25%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 387,075
Open 50.00
Bid (Size) 48.20 (1)
Ask (Size) 51.09 (1)
Prev. Close 50.23
Today's Range 49.34 - 51.15
52wk Range 30.66 - 54.86
Shares Outstanding 59,762,106
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Expert Ratings for Sage Therapeutics
 
Via Benzinga
Sage Therapeutics to Present at Upcoming May Investor Conferences
From Sage Therapeutics, Inc.
Via Business Wire

Performance

YTD
+33.08%
+33.08%
1 Month
+1.97%
+1.97%
3 Month
+20.95%
+20.95%
6 Month
+30.80%
+30.80%
1 Year
+58.62%
+58.62%

More News

Read More
Sage Therapeutics Announces First Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics's Earnings Outlook
Via Benzinga
Sage Therapeutics to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023
From Sage Therapeutics, Inc.
Via Business Wire
What 5 Analyst Ratings Have To Say About Sage Therapeutics
Via Benzinga
Earnings Scheduled For February 16, 2023
Via Benzinga
Expert Ratings for Sage Therapeutics
Via Benzinga
Sage Therapeutics to Present at the Stifel 2023 CNS Days
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics Appoints Jessica Federer to Board of Directors
From Sage Therapeutics, Inc.
Via Business Wire
Analyst Creates Bullish Pitch For Sage Therapeutics Around Greater Enthusiasm For Its Depression Drug, Zuranolone
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 13, 2023
Via Benzinga
Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Illumina, Seagen And Other Big Stocks Moving Higher On Monday
Via Benzinga
Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics Announces European Medicines Agency Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics-Biogen Partnered Depression Candidate Under Priority FDA Review, Analyst Says Its 'Incrementally Positive'
Via Benzinga
Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
From Sage Therapeutics, Inc.
Via Business Wire
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
From Biogen Inc.
Via GlobeNewswire
Sage Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Provide Update on 2023 Key Initiatives at 41st Annual J.P. Morgan Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
From Sage Therapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.